Dendritic Cells Generated From Patients With Androgen-Independent Prostate Cancer Are Not Impaired in Migration and T-Cell Stimulation

Abstract

BACKGROUND<br />Dendritic cell (DC)-based vaccination has been investigated as immunotherapy for several types of cancer. A potential drawback to vaccination with autologous monocyte-derived DCs (MoDCs) could be that MoDCs from patients are functionally impaired. In case of androgen-independent prostate cancer (CaP), the cancer itself, diverse prior therapies, and the hormone manipulation may affect the immune system.<br />METHODS. MoDCs from patients suffering from androgen-independent CaP were generated<br />according to a clinically applicable protocol to evaluate the phenotype, maturation capacity,<br />migration, and T-cell stimulation of these cells compared with those generated from tumor-free<br />donors.<br /><br /><br />RESULTS<br />MoDCs generated from CaP patients could be fully matured and efficiently<br />migrated towards the chemokine CCL21. They had a strong potency to activate allogeneicCD4þ<br />and CD8þ T-cells and to present antigens to specific CTL.<br /><br /><br />CONCLUSIONS<br />Our data suggest that MoDCs from patients with androgen-independent<br />CaP are functionally intact and hence qualify as cellular vaccines for immunotherapy of advanced stage CaP.